The National Institute of Allergy and Infectious Diseases (NIAID) recently launched a study to determine whether drugs that are already approved or in the late stage of clinical development might merit testing in larger clinical trials as a coronavirus disease 2019 (COVID-19) treatment.
The ACTIV-5 Big Effect Trial is a collaboration with the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program, a public-private partnership with the National Institutes of Health. The phase 2 randomized, double-blind clinical trial will compare different therapies to a common control group to see which drugs, if any, have relatively large treatment effects.